{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T08:15:35Z","timestamp":1762157735628},"reference-count":29,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2017,1,2]]},"DOI":"10.1080\/13696998.2016.1225578","type":"journal-article","created":{"date-parts":[[2016,8,16]],"date-time":"2016-08-16T15:41:03Z","timestamp":1471362063000},"page":"63-71","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States"],"prefix":"10.1080","volume":"20","author":[{"given":"Dominick","family":"Latremouille-Viau","sequence":"first","affiliation":[{"name":"Analysis Group, Inc., Montreal, QC, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Guerin","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Montreal, QC, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Nitulescu","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Montreal, QC, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick S.","family":"Gagnon","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Montreal, QC, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J.","family":"Joseph","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,9,7]]},"reference":[{"key":"CIT0001","unstructured":"NIH National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER) stat fact sheets: Chronic Myeloid Leukemia (CML) [Internet]. 2016. http:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html. Accessed June 6, 2016"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-10-200305200-00010"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020777"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-144790"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1031107"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.03.006"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.10.61"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4920"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-3-47"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29889"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2013.09.004"},{"key":"CIT0014","unstructured":"Nilotinib Product Label. United States Food and Drug Administration (FDA). 2010. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022068s004s005lbl.pdf. Accessed November 2, 2015"},{"key":"CIT0015","unstructured":"Dasatinib Product Label. United States Food and Drug Administration (FDA). 2010. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021986s7s8lbl.pdf. Accessed November 2, 2015"},{"key":"CIT0016","unstructured":"Red Book - Wholesale Aquisition Costs (WAC) [Internet]. Truven Health Analytics Micromedex Solutions. 2016. http:\/\/micromedex.com\/products\/product-suites\/clinical-knowledge\/redbook. Accessed June 7, 2016"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2006.00139.x"},{"key":"CIT0018","unstructured":"Consumer Price Index (CPI). United States Department of Labor, Bureau of Labor Statistics. 2016. http:\/\/www.bls.gov\/cpi\/. Accessed June 15, 2016"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1002\/asmb.645"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1007\/BF00127305"},{"key":"CIT0021","unstructured":"Stock JH, Watson MW. Introduction to econometrics. 2nd ed. Boston: Pearson\/Addison Wesley; 2007. xlii, 796 p."},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4612-4380-9_2"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1080\/03610928008827941"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0b013e31802db55f"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.576238"},{"key":"CIT0027","unstructured":"Guerin A, Revol C, Ramanakumar AV, et\u00a0al. Twelve-month cost per responder (CPR) analysis of nilotinib and dasatinib as front-line therapy in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP). 56th ASH Annual Meeting and Exposition. December 6, 2014. San Francisco, CA. https:\/\/ash.confex.com\/ash\/2014\/webprogram\/Paper69591.html. Accessed April 1, 2016"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.789.789"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.11.850"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2016.1225578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T07:40:17Z","timestamp":1605080417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2016.1225578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,7]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1,2]]}},"alternative-id":["10.1080\/13696998.2016.1225578"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2016.1225578","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-08-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-08-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}